Anaerobic Power and Salbutamol

Ergogenic Athletic Performance Clinical Trial

Official title:

The Effects of High-dose Salbutamol on Anaerobic Cycling Power

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02255630
• Other study ID #: H14-02788
• Status: Completed
• Phase: N/A
• First received: September 16, 2014
• Last updated: November 9, 2016
• Start date: January 2015
• Est. completion date: August 2016

Study information

• Verified date: November 2016
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Athletes using inhaled β2-adrenoreceptor agonists (IBAs) win a disproportionate number of medals. However, most previous research has shown that β2 agonists do not improve exercise performance in either asthmatic or non-asthmatic athletes. Although the majority of these studies do not show an ergogenic effect, the small number of studies with extended exercise bouts (~60 minutes) do show an advantage. The investigators believe that a controlled yet sport-specific exercise protocol will elucidate this ergogenic effect. Because IBAs may have different effects on these two groups of athletes, the investigators will measure exercise performance in both female and male elite cyclists. The investigators hypothesize that athletes will perform better during a combination steady-state/sprint exercise task following salbutamol administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2016
• Est. primary completion date: November 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 40 Years

Eligibility

Inclusion Criteria:

• maximal oxygen consumption of =60 and =55 mL·kg-1·min-1 or =5·L·min-1 and =4·L·min-1 for men and women

Exclusion Criteria:

• pregnant women

• any history of uncontrolled respiratory or cardiac disease

• smokers

• diabetics

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Ergogenic Athletic Performance

Intervention

Other:
• Cycling Exercise

Locations

Country	Name	City	State
Canada	University of British Columbia, Environmental Physiology Laboratory	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
University of British Columbia	Natural Sciences and Engineering Research Council, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Power Output		peak power output of the final 30 seconds of the cycling bout will be assessed.	No